BeiGene's Brukin­sa wins CLL ap­proval af­ter top­ping Im­bru­vi­ca in head-to-head tri­al

The FDA green­lit BeiGene’s Brukin­sa for use in chron­ic lym­pho­cyt­ic leukemia, an ap­proval that should sub­stan­tial­ly ex­pand the mar­ket for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.